Osteoporosis in men

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 4, 2006, Pages 764-774

  Binkley, Neil ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NONE   (United States)

Author keywords

Androgens; Bisphosphonates; Estrogens; Osteoporosis; Teriparatide

Indexed keywords

EID: 33751236164     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302006000400021     Document Type: Article

References (109)

1. Anonymous. Consensus development conference: Prophylaxis and treatment of ssteoporosis. Am J Med 1990;90:107-10.
2. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32.
3. Gennari C, Seeman E. Introduction: The first international conference on osteoporosis in men Siena, Italy, February 23-25, 2001. Calcif Tissue Int 2001;69:177-8.
4. Kiebzak GM, Bienart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-22.
5. Feldstein AC, Nichols G, Orwoll E, Elmer PJ, Smith DH, Herson M, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005;16:953-62.
6. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996;144(3):255-63.
7. Cooper C, Melton LJ. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992;3:224-9.
8. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998;91:71-92.
9. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603.
10. Scane AC, Francis RM, Sutcliffe AM, Francis MJD, Rawlings DJ, Chapple CL. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos Int 1999;9:91-7.
11. Poor G, Atkinson EJ, O'Fallon WM, Melton LJI. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995;319:260-5.
12. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
13. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life, morbidity and mortality after low trauma hip fracture in men. Ann Rheum Dis 2006;65:87-92.
14. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-12.
15. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42.
16. Wehren LE, Hawkes WG, Orwig DL, Hebel JR, Zimmerman SL, Magaziner J. Gender differences in mortality after hip fracture: The role of infection. J Bone Miner Res 2003;18:2231-7.
17. Orwoll ES. Osteoporosis in men. Endocr Rev 1995;16:87-116.
18. Riggs BL, Melton LJ 3rd, Robb RA, Camp JJ, Atkinson EJ, Oberg AL, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 2004;19:1945-54.
19. Finkelstein JS. Overview of osteoporosis in men. Available at: 〈http://www.uptodate.com/patient_info/topicpages/topics/2092819.asp〉. Accessed in January 15, 2002.
20. Burger H, de Laet CE, van Daele PL, Weel AE, Witteman JC, Hofman A, et al. Risk factors for increased bone loss in an elderly population. Am J Epidemiol 1998;147(9):871-9.
21. Kamel HK. Male osteoporosis: New trends in diagnosis and therapy. Drugs Aging 2005;22:741-8.
22. Seeman E. The dilemma of osteoporosis in men. Am J Med 1995;98(suppl. 2A):76S-88S.
23. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69(3):523-7.
24. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
25. Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003;88:1497-502.
26. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 2005;20:1785-91.
27. Khosla S, Melton LJI, Riggs BL. Estrogens and bone health in men. Calcif Tissue Int 2001;69:189-92.
28. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331(16):1056-61.
29. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80(12):3689-98.
30. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599-603.
31. Rochira V, Faustini-Fustini M, Balestrieri A, Carani C. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J Clin Endocrinol Metab 2000;35(5):1841-5.
32. Falahatik-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;106:1553-60.
33. Kelepouris N, Harper KD, Gannon F, Kaplan FS, Haddad JG. Severe osteoporosis in men. Ann Intern Med 1995;123(6):452-60.
34. Compston J. Secondary causes of osteoporosis in men. Calcif Tissue Int 2001;69:193-5.
35. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton LJI. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994;15(5):551-5.
36. Vanderschueren D, Boonen S, Bouillon R. Osteoporosis and osteoporotic fractures in men: A clinical perspective. Baillieres Clin Endocrinol Metab 2000;14:299-315.
37. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997;82(9):2799-805.
38. Ciria-Recasens M, Perez-Edo L, Blanch-Rubio J, Marinoso ML, Benito-Ruiz P, Serrano S, et al. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone 2005;36:926-30.
39. Pernow Y, Granberg B, Saaf M, Weidenhielm L. Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int 2006;78:90-7.
40. Van Pottelbergh I, Goemaere S, Zmierczak H, Kaufman JM. Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab 2004;89:4949-53.
41. Patel MBR, Arden NK, Masterson LM, Phillips DI, Swaminathan R, Syddall HE, et al. Investigating the role of the growth hormone-insulin-like growth factor (GH-IGF) axis as a determinant of male bone mineral density (BMD). Bone 2005;37:833-41.
42. Ferrari SL, Deutsch S, Baudoin C, Cohen-Solal M, Ostertag A, Antonarakis SE, et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 2005;37(6):770-5.
43. Diaz MN, O'Neill TW, Silman AJ. The influence of family history of hip fracture on the risk of vertebral deformity in men and women: the European Vertebral Osteoporosis Study. Bone 1997;20(2):145-9.
44. Cohen-Solal ME, Baudoin C, Omouri M, Kuntz D, De Vernejoul MC. Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res 1998;13(12):1909-14.
45. Kanis JA, Melton LJI, Christiansen C, Johnston CC, Khaltaev N. Perspective: The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137-41.
46. Melton LJI, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res 1998;13(12):1915-23.
47. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD. Bone mineral density predicts osteoporotic fractures in elderly men: The MINOS study. Osteoporos Int 2005;16:1184-92.
48. Binkley N, Schmeer P, Wasnich R, Lenchik L. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom 2002;5(suppl.):s19-s27.
49. Leslie WD, Adler RA, El-Hajj Fuleihan G, Hodsman AB, Kendler DL, McClung M, et al. Application of the 1994 WHO Classification to Populations other than postmenopausal Caucasian women: The 2005 ISCD Official Positions. J Clin Densitom 2006;9(1):22-30.
50. Drinka PJ, DeSmet AA, Bauwens SF, Rogot A. The effect of overlying calcification on lumbar bone densitometry. Calcif Tissue Int 1992;50:507-10.
51. Kanis JA, Gluer C-C. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000;11:192-202.
52. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 1999;10:259-64.
53. The Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women and children. J Clin Densitom 2004;7:17-26.
54. Wiemann L, Krueger D, Vallarta-Ast N, Binkley N. Effect of female database use for T-score derivation in men. 2006.
55. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom 2004;7:1-5.
56. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167(10 suppl):S1-S34.
57. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.
58. Johnell O, De Laet C, Johansson H, et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002;13(suppl):S14.
59. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 2001;69:218-21.
60. McClung MR. Do current management strategies and guidelines adequately address fracture risk? Bone 2006;38:S13-7.
61. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 2005;16:6-14.
62. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003;67:1521-6.
63. Holick MF. Vitamin D: A millennium perspective. J Cell Biochem 2003;88:296-307.
64. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-10.
65. Bilezikian JP, Kurland ES, Rosen CJ. Male skeletal health and osteoporosis. Trends Endocrinol Metab 1999;10(6):244-50.
66. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: The Dubbo osteoporosis epidemiology study. J Bone Miner Res 2005;20:579-87.
67. Anonymous. Health, United States, 2005 with chartbook on trends in the health of Americans. Available at: 〈http://www.cdc.gov/nchs/faststats/ lifexpec.htm〉. Accessed in May 15, 2005.
68. Harris D, Haboubi N. Malnutrition screening in the elderly population. J R Soc Med 2005;98:411-4.
69. Delmi M, Rapin CH, Bengoa JM, Delmas PD, Vasey H, Bonjour JP. Dietary supplementation in elderly patients with fractured neck of the femur. Lancet 1990;335:1013-6.
70. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
71. Francis RM. Male osteoporosis. Rheumatology (Oxford) 2000;39:1055-9.
72. Daly RM, Brown M, Bass S, Kukuljan S, Nowson C. Calcium-and vitamin D3-fortified milk reduces bone loss at clinically relevant sites in older men: A 2-year randomized controlled trial. J Bone Miner Res 2006;21:397-405.
73. Anonymous. Physician's guide to prevention and treatment of osteoporosis. Available at: 〈http://www.nof.org/physguide〉. Accessed in April 20, 2003.
74. Levis S, Gomez A, Jimenez C, Veras L, Ma F, Lai S, et al. Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab 2005;90:1557-62.
75. Heaney RP. Vitamin D: how much do we need, and how much is too much. Osteoporos Int 2000;11:553-5.
76. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
77. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomized double blind controlled trial. Br Med J 2003;326:469-74.
78. Al-Oanzi ZH, Tuck SP, Raj N, Harrop JS, Summers GD, Cook DB, et al. Assessment of vitamin D status in male osteoporosis. Clin Chem 2006;52:248-54.
79. Heaney RP. Phosphorus nutrition and the treatment of osteoporosis. Mayo Clin Proc 2004;79:91-7.
80. Karlsson MK. Skeletal effects of exercise in men. Calcif Tissue Int 2001;69:196-9.
81. Tinetti ME. Preventing falls in elderly persons. N Engl J Med 2003;348:42-9.
82. Anonymous. The American Geriatrics Society, British Geriatrics Society and American Academy of Orthopedic Surgeons. 2001 Guideline for the prevention of falls in older persons. Annals of Long-Term Care 2001;11:42-54.
83. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993;341:11-3.
84. Parker MJ, Gillespie WJ, Gillespie LD. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2005;20;(3):CD001255.
85. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf) 2004;60:653-70.
86. Hijazi RA, Cunningham GR. Andropause: Is androgen replacement therapy indicated for the aging male? Annu Rev Med 2005;56:117-37.
87. Harman SM, Metter EJ, Tobin JD. Longitudinal effects of aging on serum total and free T levels in healthy men. J Clin Endocrinol Metab 2001;86:724-31.
88. Anonymous. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocrine Practice 2002;8:439-56.
89. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84(6):1966-72.
90. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-93.
91. Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152:881-6.
92. Francis RM. Androgen replacement in aging men. Calcif Tissue Int 2001;69:235-8.
93. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol Med Sci 2005;60A:1451-7.
94. Schlegel PN, Hardy MP. Androgen replacement overview and current guidelines. J Androl 2006;27:125.
95. Wald M, Meacham RB, Ross LS, Niederberger CS. Testosterone replacement therapy for older men. J Androl 2006;27:126-32.
96. Jockenhovel F. Testosterone therapy - What, when and to whom? Aging Male 2004;7:319-24.
97. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.
98. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
99. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-3.
100. Ringe J, Faber H, Salem M, Grauer A, Moller G. Risedronate therapy reduces the risk of new vertebral fractures by 60% in osteoporotic men with osteoporosis within 1 year. J Bone Miner Res 2004;19(suppl. 1):s441.
101. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-7.
102. Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 2004;24:333-341.
103. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
104. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005;165:1743-8.
105. Bauer DC, Orwoll E. Quality indicators for management of osteoporosis. Ann Intern Med 2002;137:621-2.
106. Kurland ES, Cosman F, McMahon D, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85(9):3069-76.
107. Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, et al. Brief therapy with recombinant human parathyroid hormone (1-34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteopenia or osteoporosis. J Bone Miner Res 2001;16(suppl. 1):S221.
108. Orwoll ES. Treatment of osteoporosis in men. Calcif Tissue Int 2004;72:114-9.
109. Colon-Emeric C, Yballe L, Sloane R, Pieper CF, Lyles KW. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture. J Am Geriatr Soc 2000;48:1261-3.